Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark Frewin is active.

Publication


Featured researches published by Mark Frewin.


Proceedings of the National Academy of Sciences of the United States of America | 2003

Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells

Masahide Tone; Yukiko Tone; Elizabeth Adams; Stephen F. Yates; Mark Frewin; Stephen P. Cobbold; Herman Waldmann

Recently, agonist antibodies to glucocorticoid-induced tumor necrosis factor receptor (GITR) (tumor necrosis factor receptor superfamily 18) have been shown to neutralize the suppressive activity of CD4+CD25+ regulatory T cells. It was anticipated that this would be the role of the physiological ligand. We have identified and expressed the gene for mouse GITR ligand and have confirmed that its interaction with GITR reverses suppression by CD4+CD25+ T cells. It also, however, provides a costimulatory signal for the antigen-driven proliferation of naïve T cells and polarized T helper 1 and T helper 2 clones. RT-PCR and mAb staining revealed mouse GITR ligand expression in dendritic cells, macrophages, and B cells. Expression was controlled by the transcription factor NF-1 and potentially by alternative splicing of mRNA destabilization sequences.


Immunological Reviews | 2003

Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms.

Stephen P. Cobbold; Kathleen F. Nolan; Luis Graca; Raquel Castejon; Alain Le Moine; Mark Frewin; Susan Humm; Elizabeth Adams; Sara A. J. Thompson; Diana Zelenika; Alison M. Paterson; Stephen F. Yates; Paul J. Fairchild; Herman Waldmann

Summary:  Transplantation tolerance can be induced in adult rodents using monoclonal antibodies against coreceptor or costimulation molecules on the surface of T cells. There are currently two well‐characterized populations of T cells, demonstrating regulatory capacity: the ‘natural’ CD4+CD25+ T cells and the interleukin (IL)‐10‐producing Tr1 cells. Although both types of regulatory T cells can induce transplantation tolerance under appropriate conditions, it is not clear whether either one plays any role in drug‐induced dominant tolerance, primarily due to a lack of clear‐cut molecular or functional markers. Similarly, although dendritic cells (DCs) can be pharmacologically manipulated to promote tolerance, the phenotype of such populations remains poorly defined. We have used serial analysis of gene expression (SAGE) with 29 different T‐cell and antigen‐presenting cell libraries to identify gene‐expression signatures associated with immune regulation. We found that independently derived, regulatory Tr1‐like clones were highly concordant in their patterns of gene expression but were quite distinct from CD4+CD25+ regulatory T cells from the spleen. DCs that were treated with the tolerance‐enhancing agents IL‐10 or vitamin D3 expressed a gene signature reflecting a functional specification in common with the most immature DCs derived from embryonic stem cells.


The New England Journal of Medicine | 2005

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Bart Keymeulen; E. Vandemeulebroucke; Anette-G. Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans K. Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandené; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud


Journal of Immunology | 1999

Elimination of the Immunogenicity of Therapeutic Antibodies

Lisa K. Gilliland; Louise Walsh; Mark Frewin; Matt P. Wise; Masahide Tone; Geoff Hale; Dimitris Kioussis; Waldmann H


Clinical Immunology | 1999

Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation.

C.M Lockwood; J.D Elliott; L Brettman; Geoff Hale; Peppy Rebello; Mark Frewin; D Ringler; C Merrill; Herman Waldmann


Archive | 2006

Methods of treatment using anti-CD3 antibodies

Herman Waldmann; Mark Frewin


Archive | 1999

Hybrid human/rodent igg antibody to cd3, and methods of its construction

Herman Waldmann; Mark Frewin


Archive | 2002

TRX1 antibody and uses therefor

Mark Frewin; Herman Waldmann; Scott David Gorman; G Hale; Patricia Rao; Tadeusz Kornaga; Douglas J. Ringler; Stephen P. Cobbold; Dawn Winsor-Hines


Archive | 2004

Compositions and methods of tolerizing a primate to an antigen

Mark Frewin; Herman Waldmann; Scott David Gorman; G Hale; Patricia Rao; Tadeusz Kornaga; Douglas J. Ringler; Stephen P. Cobbold; Dawn Winsor-Hines


Archive | 2003

Therapeutic antibodies with reduced side effects

Herman Waldmann; Mark Frewin; Lisa K. Gilliland; Silva Graca Luis Richardo Simoes Da

Collaboration


Dive into the Mark Frewin's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

G Hale

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar

Patricia Rao

University of Cambridge

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge